NCT01502124 is a Phase 3 clinical trial of somatropin in Growth Hormone Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01502124?

NCT01502124 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01502124?

Interventions in NCT01502124: somatropin, somatropin.

What condition does NCT01502124 study?

NCT01502124 studies Growth Hormone Disorder, Growth Hormone Deficiency in Children.

Is NCT01502124 still recruiting?

NCT01502124 is currently completed. Last updated 28 February 2017.

Last reviewed 2017-02-28 · How we verify

NCT01502124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

Completed Phase 3 Last updated 28 February 2017

What this trial tests

Phase 3 trial testing somatropin in Growth Hormone Disorder in 78 participants. Completed in 5 March 2003.

Timeline

8 May 2001

Primary endpoint
5 March 2003

5 March 2003

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	8 May 2001
Primary completion	5 March 2003
Estimated completion	5 March 2003
Sites	21 locations across United States

Drugs / interventions tested

somatropin (Somatropin) — full drug profile →
somatropin (Somatropin) — full drug profile →

Conditions studied

Growth Hormone Disorder — all drugs for Growth Hormone Disorder →
Growth Hormone Deficiency in Children — all drugs for Growth Hormone Deficiency in Children →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 3 to 17, any sex, with Growth Hormone Disorder or Growth Hormone Deficiency in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of somatropin

Trials testing the same drug.

NCT02726542 — Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents · EARLY_PHASE1 · completed
NCT02382939 — A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Prev · Phase 3 · completed
NCT02229851 — Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropi · Phase 3 · completed
NCT02092077 — A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children · Phase 2 · terminated
NCT01973244 — A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth · Phase 1 · completed

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01502124 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 28 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01502124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing